Stock XERS XERIS BIOPHARMA HOLDINGS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Xeris Biopharma Holdings, Inc.

Equities

XERS

US98422E1038

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-07-12 pm EDT 		5-day change 1st Jan Change
2.355 USD +0.64% Intraday chart for Xeris Biopharma Holdings, Inc. +11.61% +0.21%
Jul. 08 Xeris Biopharma Appoints John Shannon as CEO MT
Jul. 08 Xeris Biopharma Holdings, Inc. Announces CEO Changes CI

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Xeris Biopharma Appoints John Shannon as CEO
Xeris Biopharma Holdings, Inc. Announces CEO Changes
Xeris Biopharma Holdings, Inc. Announces Executive Changes
Sector Update: Health Care Stocks Higher in Afternoon Trading
Xeris Biopharma Says Potential Levothyroxine Injection Preferred Over Oral Formulation; Shares Rise
Xeris Biopharma Announces Positive Topline Phase 2 Clinical Data of Its Investigational XeriSol-Formulated Once-Weekly Subcutaneous (SC) Levothyroxine (XP-8121)
Xeris Biopharma Holdings, Inc. Provides Revenue Guidance for the Full Year 2024
Xeris Biopharma Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Xeris Biopharma Collaborating With Beta Bionics for Development, Commercialization of Glucagon Product
Xeris Biopharma Holdings, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023
Xeris Biopharma Holdings, Inc. Provides Earnings Guidance for the Year 2024
Xeris Biopharma Holdings Seeks Acquisitions
US Equity Markets Close Higher Wednesday as Investors Await Inflation Data
Sector Update: Health Care Stocks Gain Late Afternoon
Xeris Biopharma Shares Rise on Licensing Agreement With Amgen
Xeris Biopharma Enters into an Exclusive Worldwide License Agreement for Xeriject Formulation of Teprotumumab
Sector Update: Health Care Stocks Stronger Late Afternoon
Sector Update: Health Care Stocks Gain Thursday Afternoon
Sector Update: Health Care
Xeris Biopharma Expects 2023 Revenue to be at High End of Previous Guidance; Shares Jump
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. XERS Stock
  4. News Xeris Biopharma Holdings, Inc.
  5. Other languages